Results 41 to 50 of about 12,163 (157)

Novel vaccination strategies based on recombinant Mycobacterium bovis BCG

International Journal of Medical Microbiology, 2003
In this manuscript, we will review the utilization of Mycobacterium bovis Bacille Calmette-Guerin (BCG) as a vaccine against tuberculosis (TB) and as a carrier system for heterologous antigens. BCG is one of the most widely used vaccines. Novel techniques in genome manipulation allow the construction of virulence-attenuated recombinant (r)-BCG strains ...
Guido, Dietrich, Jean-Francois, Viret, Jürgen, Hess   +2 more
openaire   +2 more sources

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis [PDF]

Nature Medicine, 2003
The live tuberculosis vaccines Mycobacterium bovis BCG (bacille Calmette-Guérin) and Mycobacterium microti both lack the potent, secreted T-cell antigens ESAT-6 (6-kDa early secretory antigenic target) and CFP-10 (10-kDa culture filtrate protein). This is a result of independent deletions in the region of deletion-1 (RD1) locus, which is intact in ...
Alexander S, Pym, Priscille, Brodin, Laleh, Majlessi, Roland, Brosch, Caroline, Demangel, Ann, Williams, Karen E, Griffiths, Gilles, Marchal, Claude, Leclerc, Stewart T, Cole   +9 more
openaire   +2 more sources

Vaccination with a BCG strain overexpressing Ag85B protects cattle against Mycobacterium bovis challenge. [PDF]

PLoS ONE, 2012
Mycobacterium bovis is the causative agent of tuberculosis in cattle but also infects other animals, including humans. Previous studies in cattle have demonstrated that the protection induced by BCG is not complete.
Caroline Rizzi, María Verónica Bianco, Federico Carlos Blanco, Marcelo Soria, María José Gravisaco, Valeria Montenegro, Lucas Vagnoni, Bryce Buddle, Sergio Garbaccio, Fernando Delgado, Karen Silva Leal, Angel Adrián Cataldi, Odir Antônio Dellagostin, Fabiana Bigi   +13 more
doaj   +1 more source

Attenuated Bacteria‐Based Tumor Therapy: Clinical Application Risks, Marketing Approval Restrictions, and Coping Strategies

Advanced Science, Volume 13, Issue 16, 18 March 2026.
This review comprehensively overviews attenuated bacteria‐based tumor therapy, highlighting key methodologies and recent progress. It examines strategies for enhancing safety, stabilizing efficacy, optimizing manufacturing, and navigating regulatory pathways.
Yucheng Liu, Junhong Yao, Jiaxin Deng, Minjie Zhou, Kaiyue Shen, Shishuo Sun, Xiaoge Gao, Qing Zhang, Haiheng Xu   +8 more
wiley   +1 more source

A century of BCG vaccination: Immune mechanisms, animal models, non-traditional routes and implications for COVID-19

Frontiers in Immunology, 2022
Bacillus Calmette-Guerin (BCG) has been used as a vaccine against tuberculosis since 1921 and remains the only currently approved vaccine for this infection.
Shivani Singh, Shivani Singh, Shivani Singh, Noemi Alejandra Saavedra-Avila, Sangeeta Tiwari, Steven A. Porcelli, Steven A. Porcelli   +6 more
doaj   +1 more source

The Current Landscape and Future Prospects of Vaccine Manufacturing in Africa: Challenges, Innovations, and Opportunities: A Narrative Review

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aims Africa has significant challenges in meeting its vaccination needs, including inadequate manufacturing capacity, infrastructure deficiencies, a scarcity of experienced personnel, regulatory hurdles, restricted access to technology and intellectual property.
Courage Chandipwisa, Agness Shimilimo, Olivier Uwishema, Helen Onyeaka   +3 more
wiley   +1 more source

Auxotrophic Mycobacterium bovis BCG: Updates and Perspectives

Vaccines, 2022
Mycobacterium bovis BCG has been used for a century as the only licensed vaccine against tuberculosis. Owing to its strong adjuvant properties, BCG has also been employed as an oncological immunotherapeutic as well as a live vaccine vector against other ...
Odir Antônio Dellagostin, Sibele Borsuk, Thaís Larré Oliveira, Fabiana Kömmling Seixas   +3 more
doaj   +1 more source

Multiscale Nanocellulosic Biomaterials in Therapeutics and Food Sciences

Small Structures, Volume 7, Issue 3, March 2026.
Multiscale nanocellulosic biomaterials offer exceptional physicochemical, mechanical, and biological properties; enabling transformative advances in therapeutics and food sciences. This review summarizes their structure–property relationships, key applications in drug delivery, tissue engineering, and food technology. Additionally, it outlines emerging
Hemant Singh, Blaise Tardy, Bruno Dufau Mattos, Shivi Tripathi, Mohd Hasan Mujahid, Sai Kumar Tammina, Narayan Chandra Mishra, Himanshu Sekhar Nanda, Fawzi Banat, Shabir Hassan   +9 more
wiley   +1 more source

A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein [PDF]

Clinical Diagnostic Laboratory Immunology, 1996
To better understand intracellular and extracellular trafficking of Mycobacterium bovis bacillus Calmette-Guérin (BCG) when used as an intravesical agent in the treatment of transitional cell carcinoma (TCC) of the bladder, recombinant BCG (rBCG) expressing the jellyfish green fluorescent protein (GFP) was created.
Y, Luo, A, Szilvasi, X, Chen, W C, DeWolf, M A, O'Donnell   +4 more
openaire   +2 more sources

Biofilm Associated Persistence and Drug Tolerance in Mycobacteria Within Host Microenvironments

APMIS, Volume 134, Issue 3, March 2026.
ABSTRACT Biofilms formed by mycobacteria, particularly Mycobacterium tuberculosis (Mtb), represent a major challenge in tuberculosis (TB) treatment due to their highly organized structure and their capacity to induce phenotypic drug tolerance. These three‐dimensional bacterial aggregates are embedded in a self‐produced extracellular matrix that ...
Lourdes Serrano Garcia, Cesar Augusto Roque‐Borda, Fernando Rogério Pavan, Marlus Chorilli   +3 more
wiley   +1 more source